Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

B.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.

On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1 combination program, which includes the previously announced ENCORE 607 registration trial in non-small cell lung cancer (NSCLC).

You May Also Be Interested In

• Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
• UiPath Inc. (PATH) PT Lowered to $14 at Truist Securities
• Pepsico (PEP) PT Lowered to $161 at BNP Paribas Exane, 'Expect Renewed Calls for Greater Urgency in NA'